Airway inflammation and tiotropium treatment in stable COPD patients

Basit Öğe Kaydı
dc.authoridKaramanli, Harun/0000-0001-5453-1526
dc.contributor.authorOzol, Duygu
dc.contributor.authorKaramanli, Harun
dc.contributor.authorUysal, Sema
dc.contributor.authorYigitoglu, Muhammet Ramazan
dc.contributor.authorYildirim, Zeki
dc.date.accessioned2025-10-24T18:09:51Z
dc.date.available2025-10-24T18:09:51Z
dc.date.issued2014
dc.departmentMalatya Turgut Özal Üniversitesi
dc.description.abstractBackground/aim: Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the lung associated with progressive airflow limitation. The aim of this study is to assess the influence of tiotropium treatment on airway inflammation and symptoms in stable COPD patients. Materials and methods: Inflammatory markers were measured in the expired breath condensate fluid (EBC) before starting tiotropium treatment and at the end of the first month. Results: Twenty-two patients (81% men). with a mean age of 65.4 +/- 10.1 years completed the study. The mean nitrotyrosine and 8-isoprostane levels for oxidative stress markers in EBC before and after treatment were 4.5 +/- 2.3, 3.5 +/- 1.9 pg/mL (P = 0.06) and 7.3 +/- 10.8, 8.1 +/- 11.7 pg/mL (P = 0.28), respectively. The mean interleukin-6 and tumor necrosis factor-alpha levels for inflammation markers in EBC before and after treatment were 1.03 +/- 1.1, 0.77 +/- 0.8 pg/mL (P = 0.41) and 27.8 +/- 2.6, 29.2 +/- 5.7 pg/mL (P = 0.36) respectively. The mean symptom scores decreased significantly with tiotropium and a mean increase of 124.6 +/- 0.86 mL was observed in a lung function test (FEV1). Conclusion: Although a 4-week treatment with tiotropium did not modify any of the inflammatory or oxidative stress markers in EBC fluid, tiotropium treatment helps to control symptoms in COPD.
dc.description.sponsorshipFatih University Project Office [P53010905_1]
dc.description.sponsorshipThis study was supported by the Fatih University Project Office (P53010905_1).
dc.identifier.doi10.3906/sag-1303-138
dc.identifier.endpage808
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5
dc.identifier.pmid25539549
dc.identifier.scopus2-s2.0-84905638643
dc.identifier.scopusqualityQ1
dc.identifier.startpage804
dc.identifier.trdizinid213176
dc.identifier.urihttps://doi.org/10.3906/sag-1303-138
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/213176
dc.identifier.urihttps://hdl.handle.net/20.500.12899/3860
dc.identifier.volume44
dc.identifier.wosWOS:000343068800015
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.relation.ispartofTurkish Journal Of Medical Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20251023
dc.subjectTiotropium; inflammation; airways; COPD
dc.titleAirway inflammation and tiotropium treatment in stable COPD patients
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu